AnaptysBio Holds 2025 Annual Stockholders Meeting

AnaptysBio ( (ANAB) ) just unveiled an update.

On June 17, 2025, AnaptysBio, Inc. held its 2025 Annual Meeting of Stockholders where several key proposals were adopted. These included the election of three Class II directors, the ratification of KPMG LLP as the independent registered public accounting firm, and the approval of amendments to the company’s 2017 Equity Incentive Plan. The meeting also featured non-binding advisory votes on executive compensation and the frequency of future advisory votes concerning executive compensation. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (ANAB) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on AnaptysBio stock, see the ANAB Stock Forecast page.

Spark’s Take on ANAB Stock

According to Spark, TipRanks’ AI Analyst, ANAB is a Neutral.

The overall stock score reflects a mix of strong technical momentum and promising trial results against a backdrop of financial and valuation challenges. While the technical indicators and positive trial results are encouraging, the company’s current financial performance and negative valuation metrics dampen the overall score.

To see Spark’s full report on ANAB stock, click here.

More about AnaptysBio

AnaptysBio, Inc. operates in the biotechnology industry, focusing on the development of therapeutic antibodies for the treatment of inflammation and immune-oncology related diseases.

Average Trading Volume: 752,647

Technical Sentiment Signal: Buy

Current Market Cap: $702.2M

See more insights into ANAB stock on TipRanks’ Stock Analysis page.